Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/9/2019
Start Date:March 2, 2015
End Date:March 15, 2019

Use our guide to learn which trials are right for you!

A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy

The objective of this study is to assess efficacy and safety of radium-223 dichloride in
subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone
receptor positive breast cancer with bone metastases treated with hormonal treatment
background therapy.


Inclusion Criteria:

- Documentation of histological or cytological confirmation of estrogen receptor
positive (ER+) and HER2 negative adenocarcinoma of the breast must be available.

- Women (≥18 years of age) with metastatic breast cancer not amenable to curative
treatment by surgery or radiotherapy.

- Documentation of menopausal status: post menopausal or premenopausal subjects are
eligible.

- Subjects with bone dominant disease with at least 2 skeletal metastases identified at
baseline by bone scintigraphy and confirmed by CT/magnetic resonance imaging (MRI).
Presence of metastases in soft tissue (skin, subcutaneous, muscle, fat, lymph
nodes)and/or visceral metastases is allowed.

- Measurable or non-measurable disease (but radiologically evaluable) according to
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

- Subjects must have received at least one line of hormonal therapy in the metastatic
setting

- Subjects who are eligible for further standard of care endocrine treatment.

- Subjects enrolled in the current study must start treatment with the single hormone
agent either within 15 days prior to randomization or after randomization (before or
simultaneously to the first injection of Ra-223/placebo).

- Subjects must have experienced no more than two skeletal-related events (SREs) prior
to study entry defined as: Need for external beam radiotherapy (EBRT) tor bone,
pathological bone fracture (excluding major trauma), spinal cord compression and/or
orthopedic surgical procedure. Subjects with no prior SREs are not permitted.

- Subjects must be on therapy with bisphosphonate and denosumab. and are required to
have been on such therapy for at least 1 month before start of study treatment.

- Adequate hematological, liver and kidney function.

Exclusion Criteria:

- Subjects with Inflammatory breast cancer.

- Subjects who have either received chemotherapy for metastatic disease or are
considered by the treating investigator to be appropriate candidates for chemotherapy
as current treatment for metastatic breast cancer are excluded. Chemotherapy
administered for adjuvant/neo adjuvant disease is acceptable.

- Subjects with known or history of brain metastases or leptomeningeal disease: subjects
with neurological symptoms must undergo a contrast CT scan or MRI of the brain within
28 days prior to randomization to exclude active brain metastasis. Imaging of the
central nervous system (CNS) is otherwise not required.

- Known presence of osteonecrosis of jaw.

- Patients with immediately life-threatening visceral disease, for whom chemotherapy is
the preferred treatment option.

- Lymphangitic carcinomatosis.

- Patients with ascites requiring paracentesis within 2 weeks prior to study entry
(signature of informed consent) and during the screening period.
We found this trial at
12
sites
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Annapolis, MD
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Linz,
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Pontiac, MI
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials